Efficacy and safety of the CD40 ligand inhibitor dapirolizumab pegol in systemic lupus erythematosus (PHOENYCS GO): a randomised, double-blind, placebo-controlled, phase 3 trial

Journal:

The Lancet

Published:

2026-05-29

DOI:

10.1016/s0140-6736(26)00691-4

Affiliations:

18

Authors:

18

Go to article

Institutions	Authors	Share
UCB Pharma Limited, United Kingdom (UK)	2.000000	0.11
UCB Pharma GmbH, Germany	2.000000	0.11
Duke University, United States of America (USA)	1.000000	0.06
UCL, United Kingdom (UK)	1.000000	0.06
Oklahoma Medical Research Foundation (OMRF), United States of America (USA)	1.000000	0.06
Charité - University Medicine Berlin, Germany	1.000000	0.06
Johns Hopkins University (JHU), United States of America (USA)	1.000000	0.06
University Health Network (UHN), U of T, Canada	1.000000	0.06
Columbia University Irving Medical Center (CUIMC), CU, United States of America (USA)	1.000000	0.06
Biogen Idec Limited, United Kingdom (UK)	1.000000	0.06
Biogen, United States of America (USA)	1.000000	0.06
UCB - France, France	1.000000	0.06
UCB Inc., United States of America (USA)	1.000000	0.06
Biogen Switzerland AG, Switzerland	1.000000	0.06
University of Leeds, United Kingdom (UK)	0.500000	0.03
Leeds Teaching Hospitals NHS Trust (LTHT), United Kingdom (UK)	0.500000	0.03
Monash University, Australia	0.500000	0.03
Monash Health, Australia	0.500000	0.03

Interested in Neurosciences?